Abstract:Despite the evident progress in neonatal medicine, retinopathy of prematurity (ROP) remains a serious threat to the vision of premature infants, due to a still partial understanding of the mechanisms underlying the development of this disease and the lack of drugs capable of arresting its progression. Although ROP is a multifactorial disease, retinal vascularization is strictly dependent on oxygen concentration. The exposition of the retina of a preterm newborn, still incompletely vascularized, to an atmosphere relatively hyperoxic, as the extrauterine environment, induces the downregulation of proangiogenic factors and therefore the interruption of vascularization (first ischemic phase of ROP). However, over the following weeks, the growing metabolic requirement of this ischemic retina produces a progressive hypoxia that specularly promotes the surge of proangiogenic factors, finally leading to proliferative retinopathy (second proliferative phase of ROP). The demonstration that the noradrenergic system is actively involved in the coupling between hypoxia and the induction of vasculogenesis paved the way for a pharmacologic intervention aimed at counteracting the interaction of noradrenaline with specific receptors and consequently the progression of ROP. A similar trend has been observed in infantile hemangiomas, the most common vascular lesion of childhood induced by pre-existing hypoxia, which shares similar characteristics with ROP. The fact that propranolol, an unselective antagonist of β1/2 adrenoceptors, counteracts the growth of infantile hemangiomas, suggested the idea of testing the efficacy of propranolol in infants with ROP. From preclinical studies, ongoing clinical trials demonstrated that topical administration of propranolol likely represents the optimal approach to reconcile its efficacy and maximum safety. Given the strict relationship between vessels and neurons, recovering retinal vascularization with propranolol may add further efficacy to prevent retinal dysfunction. In conclusion, the strategy of contrasting precociously the progression of the disease appears to be more advantageous than the current wait-and-see therapeutic approach, which instead is mainly focused on avoiding retinal detachment.

Adenosine receptors and caffeine in retinopathy of prematurity

Adenosine Receptors and Caffeine in Retinopathy of Prematurity.

Caffeine Preferentially Protects Against Oxygen-Induced Retinopathy

Targeting adenosine A2A receptors for early intervention of retinopathy of prematurity

Disruption of CD73-Derived and Equilibrative Nucleoside Transporter 1–Mediated Adenosine Signaling Exacerbates Oxygen-Induced Retinopathy

Adenosine A1 Receptors Selectively Modulate Oxygen-Induced Retinopathy at the Hyperoxic and Hypoxic Phases by Distinct Cellular Mechanisms.

The Progress of Prophylactic Treatment in Retinopathy of Prematurity

[Advances in Retinopathy of Prematurity].

Concurrent Physiological and Pathological Angiogenesis in Retinopathy of Prematurity and Emerging Therapies

Retinopathy of Prematurity—Targeting Hypoxic and Redox Signaling Pathways

Potential Effects of Nutraceuticals in Retinopathy of Prematurity

Anti-vascular endothelial growth factor treatment for retinopathy of prematurity

Application by Intravitreal and Topical Instillation

Retinopathy of prematurity: inflammation, choroidal degeneration, and novel promising therapeutic strategies

Propranolol: a new pharmacologic approach to counter retinopathy of prematurity progression

Neurovascular Abnormalities in Retinopathy of Prematurity and Emerging Therapies

Protective effects of rapamycin on the retinal vascular bed during the vaso-obliteration phase in mouse oxygen-induced retinopathy model

Abstract 177: Adenosine Receptor 2A-mediated Endothelial Glycolysis Critically Contributes to Pathological Angiogenesis of Retina

Assessment and management of retinopathy of prematurity in the era of anti-vascular endothelial growth factor (VEGF)

Natural Products in the Treatment of Retinopathy of Prematurity: Exploring Therapeutic Potentials

[Be Cautious to Treat Retinopathy of Prematurity with Anti-Vascular Endothelial Growth Factor Pharmacotherapy].